Claims
- 1. A compound of the formula: ##STR15## wherein X.sup.1 is ##STR16## or ##STR17## where R.sup.1 and R.sup.2 are independently H or ##STR18## or OR.sup.1 and OR.sup.2 together are ##STR19## provided that R.sup.1 and R.sup.2 are never simultaneously H; R.sup.4 and R.sup.5 are independently H, sodium, potassium, ammonium, C.sub.1 -C.sub.4 -alkyl-substituted-ammonium, magnesium/2, calcium/2, aluminum/3, C.sub.1 -C.sub.8 -straight or branched-chain alkyl, phenyl, phenyl-C.sub.1 -C.sub.4 -alkyl, phosphate or pyrophosphate; and
- R.sup.8 is H or ##STR20## wherein R.sup.9 is H; unsubstituted C.sub.1 -C.sub.20 -straight or branched-chain, saturated or mono- or polyunsaturated alkyl; unsubstituted or substituted phenyl, wherein the substituent(s) is/are independently halogen or C.sub.1 -C.sub.4 -alkyl; pyridyl; piperidyl; furyl; imidazolyl; tetrahydrofuryl; thienyl; phenyl-C.sub.1 -C.sub.4 -alkyl; C.sub.1 -C.sub.4 -alkoxy-C.sub.1 -C.sub.4 -alkyl; phenyloxy-C.sub.1 -C.sub.4 -alkyl; or when X.sup.1 is the structure (I), alternatively also substituted C.sub.1 -C.sub.20 -straight or mono- or polyunsaturated alkyl, wherein the substituent(s) is/are independently hydroxy, amino, or carboxyl.
- 2. A compound according to claim 1, wherein R.sup.4 is H.
- 3. A compound of Formula II of claim 1, wherein R.sup.1 or R.sup.2 is ##STR21## and R.sup.2 or R.sup.1 is H.
- 4. The compound of claim 1 which is ##STR22##
- 5. A compound of Formula I of claim 1 wherein OR.sup.1 and OR.sup.2 together are ##STR23##
- 6. A compound of Formula II of claim 1 wherein OR.sup.1 and OR.sup.2 together are ##STR24##
- 7. A method of treating a virus infection in a mammalian or avian or piscine species comprising administering a compound of claim 1, in a quantity effective to impart an anti-viral effect.
- 8. A method according to claim 7 wherein the virus is a herpes virus.
- 9. A method according to claim 7 wherein the compound is administered at from about 0.01 to about 200 mg/kg.
- 10. A method according to claim 7 wherein the compound is administered topically at a dosage level of from about 0.1% to about 5% by weight.
- 11. A method according to claim 10 wherein the dosage level is from about 0.25% to about 3% by weight.
- 12. A method according to claim 7 wherein the compound is administered orally or parenterally, at a dosage level of from about 0.8 to about 100 mg/kg.
- 13. A method according to claim 12 wherein the dosage level is from about 5 to about 50 mg/kg.
- 14. A pharmaceutical composition comprising an amount of a compound of claim 1 effective to impart an anti-viral effect and a pharmaceutically acceptable carrier.
- 15. A method according to claim 14 wherein the virus is a herpes virus.
BACKGROUND OF THE INVENTION
This application is a continuation-in-part of U.S. Ser. No. 405,634, filed Aug. 5, 1982, now abandoned which is a continuation-in-part of U.S. Ser. No. 296,604, filed Aug. 26, 1981, now abandoned.
US Referenced Citations (5)
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
405634 |
Aug 1982 |
|
Parent |
296604 |
Aug 1981 |
|